Uveal Melanoma
Conditions
Keywords
Immunotherapy, Neoadjuvant therapy, High-risk uveal melanoma, Nivolumab, Ipilimumab
Brief summary
The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.
Interventions
Nivolumab 3 mg/kg Ipilimumab 1 mg/kg
Sponsors
Inge Marie Svane
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 ≤ 80 * The patient is able to read and understand Danish. * Primary, localized and treatment-naive uveal melanoma planned for enucleation (high risk/T3-T4) and available for transvitreal biopsies. The initial diagnosis of uveal melanoma is based on ophthalmologic and clinical findings. * ECOG performance status of 0 or 1 (appendix 2) * The patient meets the following haematological and biochemical criteria at time of screening: a) AST and ALT ≤2,5 X ULN, b) Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level \> 1,5 ULN, c) Serum creatinine ≤1,5 X ULN, d) ANC (Absolute Neutrophil Count) ≥1,000/mcL, e) Platelets ≥ 75,000 /mcL, f) Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L * Signed statement of consent after receiving oral and written study information * Willingness to participate in the planned treatment and follow-up schedule * For women of childbearing potential (WOCBP) a negative serum pregnancy test at time of screening and the use of highly effective contraception is required. This applies from screening and until 6 months after treatment. The following is considered highly effective methods of contraception: 1. Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal or transdermal), 2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) 3. Intrauterine device (IUD) 4. intrauterine hormone-releasing system (IUS) 5. Bilateral tubal occlusion, 6. Vasectomised partner provided that the vasectomy is confirmed successful, 7. Sexual abstinence defined as refraining from heterosexual intercourse. WOCBP must also agree to refrain from egg donation, storage, or banking during these same time periods. \- Men with female partner of childbearing potential must: 1. Use a condom during sexual intercourse from screening and until 6 months after treatment. 2. Ensure that their partner uses a highly effective method of contraception (as described above) 3. Agree to refrain from sperm donation, storage, or banking
Exclusion criteria
* A history of prior malignancies. Patients treated for another malignancy can participate if they are without signs of disease for a minimum of 2 years after treatment. Subjects with curatively treated ductal carcinoma in situ (DCIS or LCIS) breast cancer for which they are taking hormonal therapy is acceptable. Resectable squamous or basal cell carcinoma of the skin is acceptable. * Requirement for immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to screening * The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders) * The patient is pregnant or breastfeeding * The patient has an active infection requiring systemic therapy * Significant medical disorder according to investigator; e.g severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus. * Concurrent treatment with other experimental drugs * Any significant active autoimmune disease * Severe allergy or anaphylactic reactions earlier in life * Known hypersensitivity to one of the active drugs or one or more of the excipients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs) | Until 6 months post treatment | Safety is evaluated by the Common Terminology Criteria (CTCAE) for Adverse Events version 6.0 and include the number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs) until 6 months post treatment. |
| Proportion of patients who complete the treatment regimen | Until 6 months post treatment | Feasibility is evaluated as the proportion of patients who complete the treatment regimen defined as receiving at least one dose of both nivolumab and ipilimumab, followed by enucleation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pathological response rate | through study completion, an average of 3 years | The fraction of pathological responses according to standard evaluation criteria |
| Objective response | through study completion, an average of 3 years | Size and extend of the tumor at baseline and after the second dose of nivolumab and ipilimumab. |
| Distant metastases free survival (DMFS) | Until 6 months post treatment | DMFS will be evaluated as the time from treatment initiation to the development of any distant metastasis or death. |
| Overall survival (OS) | Until 6 months post treatment | OS will be evaluated as the time from treatment initiation to death from any cause |
Countries
Denmark
Contacts
CONTACTInge Marie Svane, Professor, MD
CONTACTTine Juul Monberg, MD, PhD
Outcome results
None listed